Cytotoxic doses of ketoconazole affect expression of a subset of hepatic genes

Journal of Toxicology and Environmental Health - Part A: Current Issues

Volumn 70, Issue 22, 2007, Pages 1946-1955

  Casley, William L ^a,b   Ogrodowczyk, Carolina ^b   Larocque, Louise ^a   Jaentschke, Bozena ^a   LeBlanc Westwood, Carole ^a   Menzies, J Allan ^a   Whitehouse, Larry ^a   Hefford, Mary Alice ^a,b   Aubin, Rémy A ^a,b   Thorn, Caroline F ^c   Whitehead, Alexander S ^c   Li, Xuguang ^a,b  

^a HEALTH CANADA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; AROMATIC HYDROCARBON RECEPTOR AGONIST; DE N ACETYL KETOCONAZOLE DERIVATIVE; DRUG METABOLITE; GLUTATHIONE TRANSFERASE; HYDROCARBON; KETOCONAZOLE; PEROXISOME PROLIFERATOR; POLYCHLORINATED BIPHENYL; SERUM AMYLOID A; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DNA MICROARRAY; DRUG DOSE COMPARISON; GENE EXPRESSION; HYPOXIA; IN VITRO STUDY; LIVER; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PEROXISOME; PRIORITY JOURNAL; SINGLE DRUG DOSE; SWISS WEBSTER MOUSE;

ALDEHYDE DEHYDROGENASE; ANIMALS; ANTIFUNGAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CELL PROLIFERATION; CYTOCHROME P-450 ENZYME SYSTEM; GENE EXPRESSION; GENE EXPRESSION PROFILING; GLUTATHIONE TRANSFERASE; ISOENZYMES; KETOCONAZOLE; LIVER; MALE; MICE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SERUM AMYLOID A PROTEIN;

EID: 35648970611     PISSN: 15287394     EISSN: 10872620     Source Type: Journal    
DOI: 10.1080/15287390701551407     Document Type: Article

References (70)

1. Anderson, J. E., and Blaschke T.F., 1986. Ketoconazole inhibits cyclosporine metabolism in vivo in mice. J. Pharmacol. Exp. Ther. 236:671-674.
2. Anakk, S., Kalsotra, A., Kikuta, Y., Huang, W., Zhang, J., Staudinger, J. L., Moore, D. D., and Strobel, H. W. 2004. CAR/PXR provide directives for Cyp3a41 gene regulation differently from Cyp3a11. Pharmacogenom. J. 4:91-101.
3. Asgari, M., and Back, D. J. 1995. Effect of azoles on the glucuronidation of zidovudine by human liver UDP-glucuronosyltransferase. J. Infect. Dis. 172:1634-1636.
4. Ashino, T., Oguro, T., Shioda, S., Horai, R., Asano, M., Sekikawa, K., Iwakura, Y., Numazawa, S., and Yoshida, T. 2004. Involvement of interleukin-6 and tumor necrosis factor alpha in CYP3A11 and 2C29 down-regulation by Bacillus Calmette-Guerin and lipopolysaccharide in mouse liver. Drug. Metab. Dispos. 32: 707-714.
5. Back, D. J., Tjia, J. F., and Abel, S. M. 1992. Azoles, allylamines and drug metabolism. Br. J. Dermatol. 126(Suppl.):14-18.
6. Baldwin, A., Huang, Z., Jounaidi, Y., and Waxman, D. J. 2003. Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer. Arch. Biochem. Biophys. 409:197-206.
7. Bok, R. A., and Small, E. J. 1999. The treatment of advanced prostate cancer with ketoconazole: Safety issues. Drug Safety 20:451-458.
8. Brown, M. W., Maldonado, A. L., Meredith, C. G., Speeg, K. V., Jr., 1985. Effect of ketoconazole on hepatic oxidative drug metabolism. Clin. Pharmacol. Ther. 37:290-297.
9. Calabrese, E. J. 2005. Cancer biology and hormesis: Human tumor cell lines commonly display hormetic (biphasic) dose responses. Crit. Rev. Toxicol. 35:463-582.
10. Courselaud, B., Pigeon, C., Inoue, Y., Inoue, J., Gonzalez, F.J., Leroyer, P., Gilot, D., Boudjema, K., Guguen-Guillouzo, C., Brissot, P., Loreal, O., and Ilyin, G. 2002. C/EBPalpha regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism. Cross-talk between C/EBP pathway and iron metabolism. J. Biol. Chem. 277:41163-41170.
11. Coward, P., Wada, H. G., Falk, M. S., Chan, S.D., Meng, F., Akil, H., Conklin, B. R. 1998. Controlling signaling with a specifically designed Gi-coupled receptor. Proc. Natl. Acad. Sci. USA 95:352-357.
12. Cupp-Vickery, J. R., Garcia, C., Hofacre, A., and McGee-Estrada, K. 2001. Ketoconazole-induced conformational changes in the active site of cytochrome P450eryF. J. Mol. Biol. 311:101-110.
13. Daneshmend, T. K., and Warnock, D. W. 1988. Clinical pharmacokinetics of ketoconazole. Clin. Pharmacokinet. 141:13-34.
14. Engels, F. K., Ten Tije, A. J., Baker, S. D., Lee, C. K., Loos, W. J., Vulto, A. G., Verweij, J., and Sparreboom, A. 2004. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin. Pharmacol. Ther. 75:448-454.
15. Evans, W. E., and Relling, M. V. 1999. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 286:487-491.
16. Feldman, D. 1986. Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. Endocr. Rev. 7:409-420.
17. Finta, C., and Zaphiropoulos, P. G. 2000. The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene 260:13-23.
18. Ganz, T. 2006. Hepcidin - A peptide hormone at the interface of innate immunity and iron metabolism. Curr. Top. Microbiol. Immunol. 306:183-198.
19. Georgopapadakou, N. H., Dix, B. A., Smith, S. A., Freudenberger, J., and Funke, P. T. 1987. Effect of antifungal agents on lipid biosynthesis and membrane integrity in Candida albicans. Antimicrob. Agents Chemother. 31:46-51.
20. Glynn, A. M., Slaughter, R.L., Brass, C., D'Ambrosio, R., and Jusko, W. J. 1986. Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion. Clin. Pharmacol. Ther. 39:654-659.
21. Gonzalez, F. J., Liu, S. Y., and Yano, M. 1993. Regulation of cytochrome P450 genes: Molecular mechanisms. Pharmacogenetics 3:51-57.
22. Hayes, K. R., Vollrath, A. L., Zastrow, G. M., McMillan, B. J., Craven, M., Jovanovich, S., Rank, D. R., Penn, S., Walisser, J. A., Reddy, J. K., Thomas, R. S., and Bradfield, C. A. 2005. EDGE: A centralized resource for the comparison, analysis, and distribution of toxicogenomic information. Mol. Pharmacol. 67:1360-1368.
23. Jensen, L. E., and Whitehead, A. S. 1998. Regulation of serum amyloid A protein expression during the acute-phase response. Biochem. J. 334:489-503.
24. Klein, C., Wustefeld, T., Assmus, U., Roskams, T., Rose-John, S., Muller, M., Manns, M. P., Ernst, M., and Trautwein, C. 2005. The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. J. Clin. Invest. 115:860-869.
25. Knight, J. 2001. When the chips are down. Nature 410:860-861.
26. Kothapalli, R., Yoder, S. J., Mane, S., and Loughran, T. P., Jr. 2002. Microarray results: How accurate are they? BMC Bioinformatics 3:22.
27. Kraemer, F. B., and Spilman, S. D. 1986. Effects of ketoconazole on cholesterol synthesis. J. Pharmacol. Exp. Ther. 238:905-911.
28. Kreis, W., Budman, D. R., and Calabro, A. 2001. A reexamination of PSC 833 (Valspodar) as a cytotoxic agent and in combination with anticancer agents. Cancer. Chemother. Pharmacol. 47:78-82.
29. Kuo, W. P., Jenssen, T., Butte, A. J., Ohno-Machado, L., and Kohane, I. S. 2002. Analysis of matched mRNA measurements from two different microarray technologies. Bioinformatics 18:405-412.
30. Kurokohchi, K., Nishioka, M., and Ichikawa, M. Y. 1992. Inhibition mechanism of reconstituted cytochrome P-450scc-linked monooxygenase system by antimycotic reagents and other inhibitors. J. Steroid Biochem. Mol. Biol. 42:287-292.
31. Lahvis, G. P., Lindell, S. L., Thomas, R. S., McCuskey, R. S., Murphy, C., Glover, E., Bentz, M., Southard, J., Bradfield, C. A. 2000. Portosystemic shunting and persistent fetal vascular structures in aryl hydrocarbon receptor-deficient mice. Proc. Natl. Acad. Sci. USA 97:10442-10447.
32. Lathia, C., Lettieri, J., Cihon, F., Gallentine, M., Radtke, M., and Sundaresan, P. 2006. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer. Chemother. Pharmacol. 57:685-692.
33. Lavrijsen, K., Van Houdt, J., Thijs, D., Meuldermans, W., and Heykants, J. 1986. Induction potential of antifungals containing an imidazole or triazole moiety. Miconazole and ketoconazole, but not itraconazole are able to induce hepatic drug metabolizing enzymes of male rats at high doses. Biochem Pharmacol. 35:1867-1878.
34. Li, X., Multon, M. C., Henin, Y., Schweighoffer, F., Venot, C., Josef, J., Zhou, C., LaVecchio, J., Stuckert, P., Raab, M., Mhashilkar, A., Tocque, B., Marasco, W. A. 2000. Grb3-3 is up-regulated in HIV-1-infected T-cells and can potentiate cell activation through NFATc. J. Biol. Chem. 275:30925-30933.
35. Loose, D. S., Kan, P. B., Hirst, M. A., Marcus, R. A., and Feldman, D. 1983. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J. Clin. Invest. 71:1495-1499.
36. Mahler, C., Verhelst, J., and Denis, L. 1993. Ketoconazole and liarozole in the treatment of advanced prostatic cancer. Cancer 71:1068-1073.
37. Meek, R.L., Urieli-Shoval, S., and Benditt, E. P. 1994. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: Implications for serum amyloid A function. Proc. Natl. Acad. Sci. USA 91:3186-3190.
38. Meredith, C. G., Maldonado, A. L., and Speeg, K. V., Jr. 1985. The effect of ketoconazole on hepatic oxidative drug metabolism in the rat in vivo and in vitro. Drug Metab. Dispos. 13:156-162.
39. Moebius, U., Manns, M., Hess, G., Kober, G., Meyer zum Buschenfelde, K. H., and Meuer, S. C. 1990. T cell receptor gene rearrangements of T lymphocytes infiltrating the liver in chronic active hepatitis B and primary biliary cirrhosis (PBC): Oligoclonality of PBC-derived T cell clones. Eur. J. Immunol. 20:889-896.
40. Morita, K., Ono, T., and Shimakawa, H. 1988. Inhibitory effects of ketoconazole and miconazole on cytochrome P-450-mediated oxidative metabolism of testosterone and xenobiotics in mouse hepatic microsomes - Comparative study with cimetidine. J. Pharmacobiodyn. 11:106-114.
41. Mosca, P., Bonazzi, P., Novelli, G., Jezequel, A. M., and Orlandi, F. 1985. In vivo and in vitro inhibition of hepatic microsomal drug metabolism by ketoconazole. Br. J. Exp. Pathol. 66:737-742.
42. Nagai, K., Miyamori, I., Takeda, R., Suhara, K., and Katagiri, M. 1987. Effect of ketoconazole, etomidate and other inhibitors of steroidogenesis on cytochrome P-450sccII-catalyzed reactions. J. Steroid Biochem. 28:333-336.
43. Nakabayashi, M., Xie, W., Regan, M. M., Jackman, D. M., Kantoff, P. W., and Oh, W. K. 2006. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. Cancer 107:975-981.
44. Niemegeers, C. J., Levron, J. C., Awouters, F., and Janssen, P. A. 1981. Inhibition and induction of microsomal enzymes in rat. A comparative study of four antimycotics: Miconazole, econazole, clotrimazole and ketoconazole. Arch. Int. Pharmacodyn. Ther. 251:26-38.
45. Nelson, D. R., Zeldin, D. C., Hoffman, S. M., Maltais, L. J., Wain, H. M., and Nebert, D. W. 2004. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14:1-18.
46. Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., and Ganz, T. 2004. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 113:1271-1276.
47. Quattrochi, L. C., and Guzelian, P. S. 2001. Cyp3A regulation: From pharmacology to nuclear receptors. Drug. Metab. Dispos. 29:615-622.
48. Ritter, J. K., and Franklin, M. R. 1987. Induction and inhibition of rat hepatic drug metabolism by N-substituted imidazole drugs. Drug Metab. Dispos. 15:335-343.
49. Rodrigues, A. D., Waddell, P. R., Ah-Sing, E., Morris, B.,A., Wolf, C.,R., and Ioannides, C., 1988. Induction of the rat hepatic microsomal mixed-function oxidases by 3 imidazole-containing antifungal agents: selectivity for the cytochrome P-450IIB and P-450III families of cytochromes P-450. Toxicology 50:283-301.
50. Rodriguez, R. J., and Buckholz, C. J. 2003. Hepatotoxicity of ketoconazole in Sprague-Dawley rats: Glutathione depletion, flavin-containing monooxygenases-mediated bioactivation and hepatic covalent binding. Xenobiotica 33:429-441.
51. Ronis, M. J., Ingelman-Sundberg, M., and Badger, T. M. 1994. Induction, suppression and inhibition of multiple hepatic cytochrome P450 isozymes in the male rat and bobwhite quail (Colinus virginianus) by ergosterol biosynthesis inhibiting fungicides (EBIFs). Biochem. Pharmacol. 48:1953-1965.
52. Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C., et al. 2000. Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 24:227-234.
53. Sampol, E., Lacarelle, B., Rajaonarison, J. F., Catalin, J., and Durand, A. 1995. Comparative effects of antifungal agents on zidovudine glucuronidation by human liver microsomes. Br. J. Clin. Pharmacol. 40:83-86.
54. Sheets, J. J., and Mason, J. L. 1984. Ketoconazole: A potent inhibitor of cytochrome P-450-dependent drug metabolism in rat liver. Drug Metab. Dispos. 12:603-606.
55. Thomas, R. S., Rank, D. R., Penn, S. G., Zastrow, G. M., Hayes, K. R., Pande, K., Glover, E., Silander, T., Craven, M. W., Reddy, J. K., Jovanovich, S. B., and Bradfield, C. A. 2001. Identification of toxicologically predictive gene sets using cDNA microarrays. Mol. Pharmacol. 60:1189-1194.
56. Thomson, R. G., Rawlins, M. D., James, O. F., Wood, P., and Williams, F. M. 1988. The acute and subchronic effects of ketoconazole on hepatic microsomal monooxygenases in the rat. Biochem. Pharmacol. 37:3975-3980.
57. Thorn, C. F., and Whitehead, A. S. 2002. Differential glucocorticoid enhancement of the cytokine-driven transcriptional activation of the human acute phase serum amyloid A genes, SAA1 and SAA2. J. Immunol. 169:399-406.
58. Trachtenberg, J., and Pont, A. 1984. Ketoconazole therapy for advanced prostate cancer. Lancet 2:433-435.
59. Tsuchiya, Y., Nakajima, M., Kyo, S., Kanaya, T., Inoue, M., and Yokoi, T. 2004. Human CYP1B1 is regulated by estradiol via estrogen receptor. Cancer Res. 64:3119-3125.
60. Van Veldhuizen, P. J., Reed, G., Aggarwal, A., Baranda, J., Zulfiqar, M., and Williamson, S. 2003. Docetaxel and ketoconazole in advanced hormonere-fractory prostate carcinoma: A phase I and pharmacokinetic study. Cancer 98:1855-1862.
61. Vanden Bossche, H., Marichal, P., Odds, F. C., Le Jeune, L., and Coene, M. C. 1992. Characterization of an azole-resistant Candida glabrata isolate. Antimicrob. Agents Chemother. 36:2602-2610.
62. Wang, Y. J., Yu, C. F., Chen, L. C., Chen, C. H., Lin, J. K., Liang, Y. C., Lin, C. H., Lin, S. Y., Chen, C. F., and Ho, Y.S. 2002. Ketoconazole potentiates terfenadine-induced apoptosis in human Hep G2 cells through inhibition of cytochrome p450 3A4 activity. J. Cell Biochem. 87:147-159.
63. Wassertheil-Smoller, S. 2003. Biostatistics and epidemiology, pp. 58-65. New York: Springer-Verlag.
64. Winchell, G. A., Mistry, G. C., Kari, P. P., Marbury, T., Miller, J. L., Simpson, R. C., Rodrigues, A. D., Gottesdiener, K. M., and Wagner, J. A. 2005. The effect of ketoconazole on the pharmacokinetics of a selective alpha 1A-adrenoceptor antagonist. J. Clin. Pharmacol. 45:699-703
65. Whitehouse, L. W., Pakuts, A. P., Paul, C.J ., Mueller, R. W., and Thomas, B. H. 1990a. Hepatic effects of ketoconazole in the male Swiss Webster mouse: Temporal changes in drug metabolic parameters. Can. J. Physiol. Pharmacol. 68:1136-1142.
66. Whitehouse, L. W., Menzies, A., Dawson, B., Zamecnik, J., and Sy, W. W. 1990b. Deacetylated ketoconazole: A major ketoconazole metabolite isolated from mouse liver. J. Pharm. Biomed. Anal. 8:603-606.
67. Whitehouse, L.W., Menzies, A., Dawson, B., Cyr, T. D., By, A. W., Black, D. B., and Zamecnik, J. 1994a. Mouse hepatic metabolites of ketoconazole: isolation and structure elucidation. J. Pharm. Biomed. Anal. 12:1425-1441.
68. Whitehouse, L. W., Menzies, A., Mueller, R. W., and Pontefract, R. 1994b. Ketoconazole-induced hepatic phospholipidosis in the mouse and its association with de-N-acetyl ketoconazole. Toxicology 94:81-95.
69. Yong, W. P., Ramirez, J., Innocenti, F., and Ratain, M. J. 2005. Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes. Clin. Cancer. Res. 11:6699-6704.
70. Yuen, T., Wurmbach, E., Pfeffer, R. L., Ebersole, B. J., and Sealfon, S. C. 2002. Accuracy and calibration of commercial oligonucleotide and custom cDNA microarrays. Nucleic Acids Res. 30:e48.